Loading patent…
AssigneeResearch Development Foundation
InventorsMichael G. Rosenblum, Lawrence Cheung
Estimating the term…
The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are modified toxin compounds that are truncated and/or possess reduce antigenicity. Such designer toxins have therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins. Methods of treating cancer using these immunotoxins are provided.
-61. (canceled)
A method of killing a cancer cell comprising providing to the cell an effective amount of an immunotoxin comprising a core toxin region of gelonin and single chain antibody that specifically targets the cancer cell.
A method of treating cancer in a patient comprising administering to the patient an effective amount of a composition comprising an immunotoxin comprising a core toxin region of gelonin and single chain antibody that specifically targets a cancer cell.
A method for treating cancer in a patient comprising administering to the patient an effective amount of a composition comprising a humanized recombinant gelonin toxin.
An scFvMEL/rGel recombinant toxin fusion construct comprising SEQ ID NO:
Dependencies are inferred from the claim text.